# Sacituzumab govitecan-hziy PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy

> The next catalyst for sacituzumab govitecan-hziy, sponsored by GILEAD SCIENCES, INC. (GILD), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | sacituzumab govitecan-hziy |
| Codes | IMMU-132, GS-0132 |
| Sponsor | GILEAD SCIENCES, INC. (GILD) https://sec-api.dev/companies/gild/catalysts |
| Indications | [Locally Advanced or Metastatic Unresectable Urothelial Cancer](https://sec-api.dev/indications/locally-advanced-or-metastatic-unresectable-urothelial-cancer), [Metastatic Urothelial Cancer](https://sec-api.dev/indications/metastatic-urothelial-cancer), [Triple Negative Breast Cancer](https://sec-api.dev/indications/triple-negative-breast-cancer), Locally Advanced or Unresectable Metastatic Breast Cancer, [Endometrial Cancer](https://sec-api.dev/indications/endometrial-cancer), [Metastatic Breast Cancer](https://sec-api.dev/indications/metastatic-breast-cancer), [Solid Tumor](https://sec-api.dev/indications/solid-tumor) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### July 4, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Locally Advanced or Metastatic Unresectable Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04527991 (Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-02." https://clinicaltrials.gov/study/NCT04527991

### June 2, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Locally Advanced or Metastatic Unresectable Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04527991 (Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-04 (ACTUAL); Lead Sponsor Gilead Sciences; Results First Posted 2026-06-02." https://clinicaltrials.gov/study/NCT04527991?tab=results

### October 2026: primary completion

- Status: delayed. Date confidence: month. Stage: 2. Indication: Solid Tumor.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05119907 (Study of Sacituzumab Govitecan in Patients With Solid Tumor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05119907

### Oct 2026 to Jan 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Solid Tumor.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05119907 (Study of Sacituzumab Govitecan in Patients With Solid Tumor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05119907

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Metastatic Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT04639986

### Dec 2026 to Mar 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Metastatic Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT04639986

### February 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Triple Negative Breast Cancer; PD-L1 Positive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05382286 (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05382286

### Feb to May 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Triple Negative Breast Cancer; PD-L1 Positive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05382286 (Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05382286

### April 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05840211 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05840211

### Apr to Jul 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Locally Advanced or Unresectable Metastatic Breast Cancer; Stage IV Breast Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05840211 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05840211

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Triple Negative Breast Cancer; PD-L1 Negative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05382299 (Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05382299

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Triple Negative Breast Cancer; PD-L1 Negative.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05382299 (Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT05382299

### June 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06486441 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06486441

### Jun to Sep 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Endometrial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06486441 (Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT06486441

### April 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Metastatic Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03547973 (Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT03547973

### Apr to Jul 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Metastatic Urothelial Cancer.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03547973 (Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-04 (ESTIMATED); Lead Sponsor Gilead Sciences." https://clinicaltrials.gov/study/NCT03547973

## Same indication

- [WELIREG® (belzutifan)](https://sec-api.dev/pdufa/belzutifan) (MRK)
- [Bnt323/db-1303](https://sec-api.dev/pdufa/bnt323-db-1303) (BNTX)
- [Datopotamab deruxtecan (dato-dxd)](https://sec-api.dev/pdufa/datopotamab-deruxtecan-dato-dxd) (AZN)
- [Lasofoxifene in combination with abemaciclib](https://sec-api.dev/pdufa/lasofoxifene-in-combination-with-abemaciclib) (LONA)
- [Amtagvi® (lifileucel)](https://sec-api.dev/pdufa/lifileucel) (IOVA)
- [Pemazyre (pemigatinib)](https://sec-api.dev/pdufa/pemigatinib) (INCY)
- [Puxitatug samrotecan](https://sec-api.dev/pdufa/puxitatug-samrotecan) (AZN)
- [Rina-s](https://sec-api.dev/pdufa/rina-s) (GMAB)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Sapanisertib](https://sec-api.dev/pdufa/sapanisertib) (FTH)
- [ENHERTU (trastuzumab deruxtecan)](https://sec-api.dev/pdufa/trastuzumab-deruxtecan) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Sacituzumab govitecan-hziy PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy

```bibtex
@misc{secapidev_pdufa_sacituzumab_govitecan_hziy_20261116,
  title        = {Sacituzumab govitecan-hziy PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_sacituzumab_govitecan_hziy_20261116","title":"Sacituzumab govitecan-hziy PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
